Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexOf all the COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs), only Celebrex cancer related treatment has been approved by the FDA. In 1999, the FDA approved Celebrex as an adjunct treatment for patients with familial adenomatous polyposis (FAP). FAP is a condition whereby people begin to develop colorectal polyps which can become cancerous if the colon and other affected organs are not removed. Studies found that Celebrex cancer preventing properties were beneficial to patients with this pre-cancerous condition.
Since the approval of Celebrex for this condition, researchers have been interested in other Celebrex cancer fighting properties. In early December 2004, a team of researchers in Texas conducted a small scale study on the effects of Celebrex on breast cancer patients. Evidence from this Celebrex cancer study showed that Celebrex use lowered patient’s levels of estrogen receptors. Estrogen receptors are a marker of cell reproduction that may precede the development of cancer. The results of this study were preliminary and discovered on such a small scale (40 patients). In light of these constraints, further research must be performed before determining the extent of Celebrex cancer effectiveness.
Celebrex cancer fighting properties were also studied in an Atlanta-based medical trial. This study was published in the December 2004 issue of the Journal of the National Cancer Institute. This study allegedly claimed that Celebrex activates a chemical receptor in the body which causes cancer cells to self-destruct. This Celebrex cancer study postulated that high doses of Celebrex were necessary to achieve these cancer fighting effects.
Contrary to all the positive findings about Celebrex cancer fighting effects, Pfizer announced on December 17, 2004 that a large scale Celebrex cancer study had to be halted because of serious Celebrex risks. This Celebrex cancer study was designed to measure the effect of Celebrex use on patients with colon polyps. Researchers discovered that patients taking 400 milligrams of Celebrex a day were 2.5 times more likely to suffer a heart attack or stroke, compared to patients in the study’s control group. Patients taking 800 milligrams of Celebrex were 3.4 times more likely to suffer a life threatening cardiovascular event.
The results of this Celebrex cancer study prompted the scientific and medical communities to have serious doubts about the safety of Celebrex use in any patient population. Celebrex and other NSAIDs are primarily used to treat chronic pain conditions. Many drugs in this class have shown similar cardiovascular risks to those discovered in the Celebrex cancer study. It is still unclear whether or not the intended benefits of Celebrex cancer treatment outweigh the serious risks of cardiovascular side effects. The FDA is currently evaluating the risks and benefits of Celebrex use.
If you are interested in learning more about Celebrex cancer treatment and the possible side effects of this medication, you may wish to contact a legal professional who can advise you of your rights and options in a legal case.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...